Share on Google Plus
  3
Share on Twitter
  14
Share on Facebook
  46
Share on LinkedIn
  5
Share on PInterest Share on Fark! Share on Reddit Share on StumbleUpon Tell A Friend
  1
69 Shares     
Printer Friendly Page Save As Favorite View Favorites View Article Stats
3 comments

General News

Outrageous Pharma/Medical Conflicts of Interest

Become a Fan
  (71 fans)
By (about the author)     Permalink       (Page 1 of 2 pages)
Related Topic(s): ; ; ; ; ; ; ; ; ; ; (more...) ; , Add Tags  (less...) Add to My Group(s)

View Ratings | Rate It

Headlined to H2 4/17/14

opednews.com

A Dean of a Medical School on a Drug Company Board ?

Interview About High-Level Conflicts of Interest with Walid Gellad , MD

Walid Gellad, MD, MPH is both assistant professor of medicine and assistant professor of health policy at the University of Pittsburgh and a physician in the US Department of Veterans Affairs (VA) Pittsburgh Healthcare System. He is coauthor of a recent research letter in the Journal of the American Medical Association (JAMA) [ Academic Medical Center Leadership on Pharmaceutical Company Boards of Directors, also by Timothy Anderson, MD, Chester Good, MD, MPH and Shravan Dave, BS] that reveals almost all US large drug companies and 40 percent of all drug companies studied have leaders in academic medical centers on their boards. These drug company board members include deans, chief executive officers, department chairs, trustees at academic medical centers, school of pharmacy officials and university presidents.


Serving Two Masters by Martha Rosenberg
 

Rosenberg:

Your recent JAMA paper exposes shocking industry/academic relationships many would not expect and was covered by the Associated Press, the Milwaukee-Wisconsin Journal Sentinel and a Wall Street Journal blog. What inspired you and your colleagues to investigate this?

Gellad:

There is a lot of talk right now about physician conflicts of interest, whether the discussion is about medical students accepting pens or lunches from the pharmaceutical industry or physician consulting and speaking payments becoming public with the Physician Payment Sunshine Act. Yet the issue of dual leadership--academic medical center leaders serving on pharmaceutical company boards of directors--has not really been addressed. We investigated these relationships for 2012 using publicly available data.

Rosenberg:

Just as shocking as academic leaders serving two masters was the sheer money involved--an average of $300,000 was paid to academic leaders or members of boards of trustees serving on drug company boards. One article defending the board positions said "$300,000 is not buying anyone's ethics," but I think most of the world would disagree.

Gellad:

These amounts of compensation are typical for serving on large corporate boards. The corporate governance that board members provide includes oversight over executive leadership and fiduciary responsibility to shareholders. Remember, not all the academic leaders we found who are serving on drug company boards are deans, presidents or CEOs of hospitals. Some are on boards of trustees and not entrusted with running day-to-day operations of academic health centers--but they all had leadership roles at both academic centers and in industry. Also remember that we are not saying anything negative about academic/industry relationships in general, or necessarily about these particular relationships, but we feel that they need to be in the open and understood by the general public, patients, and doctors, just like other potential conflicts of interest"

Rosenberg:

Your paper does not spell out specific risks of these relationships. But a JAMA Viewpoint last month [by Etta Pisano, MD with the Medical University of South Carolina,   Robert Golden, MD with the University of Wisconsin and Laura Schweitzer, PhD with Union Graduate College] does. The authors ask if leaders will "direct business inappropriately" to the drug company they serve or "inappropriately use information." They also note the drug company board position would have a "chilling effect" on competing companies when it comes to business dealings.

Gellad:

Certainly there are lots of decisions that academic health center leaders make with regard to the educational, clinical and research missions of their institutions that could potentially be affected by their board positions with drug companies. Some academic medical centers have internal policies covering these relationships, perhaps requiring someone who is serving on a corporate board to recuse his or herself on certain decisions. The purpose of our paper was not to answer the question about what should or should not be done about these relationships; the purpose was to get people asking that very question.

Next Page  1  |  2

 

Martha Rosenberg is an award-winning investigative pubic health reporter who covers the food, drug and gun industries. Her first book, Born With A Junk Food Deficiency: How Flaks, Quacks and Hacks Pimp The Public Health, is distributed by Random (more...)
 

Share on Google Plus Submit to Twitter Add this Page to Facebook! Share on LinkedIn Pin It! Add this Page to Fark! Submit to Reddit Submit to Stumble Upon

The views expressed in this article are the sole responsibility of the author and do not necessarily reflect those of this website or its editors.

Writers Guidelines

Contact Author Contact Editor View Authors' Articles

Most Popular Articles by this Author:     (View All Most Popular Articles by this Author)

Grassley Investigates Lilly/WebMD link Reported by Washington Post

The Drug Store in Your Tap Water

Are You Sure You're Not Psychotic Asks Shameless Drug Company?

It's the Cymbalta Stupid

MRSA and More. Antibiotics Linked to Obesity and Allergies, Too

Another Poorly Regulated "Derivative"--the Antidepressant Pristiq

Comments

The time limit for entering new comments on this article has expired.

This limit can be removed. Our paid membership program is designed to give you many benefits, such as removing this time limit. To learn more, please click here.

Comments: Expand   Shrink   Hide  
3 people are discussing this page, with 3 comments
To view all comments:
Expand Comments
(Or you can set your preferences to show all comments, always)

How can an academic medical leader "serve" his in... by Martha Rosenberg on Thursday, Apr 17, 2014 at 10:32:07 AM
Yes, he can serve the patients. You see rotten a... by BFalcon on Friday, Apr 18, 2014 at 6:09:37 AM
Amen!  And then maybe we can get the TV ads t... by Shirley Braverman on Thursday, Apr 17, 2014 at 9:41:31 PM